California State Teachers Retirement System increased its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 0.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 82,302 shares of the biopharmaceutical company’s stock after buying an additional 302 shares during the period. California State Teachers Retirement System owned 0.14% of Agios Pharmaceuticals worth $2,667,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. State Street Corp lifted its holdings in Agios Pharmaceuticals by 6.0% during the third quarter. State Street Corp now owns 1,851,337 shares of the biopharmaceutical company’s stock valued at $59,983,000 after purchasing an additional 104,222 shares in the last quarter. First Mercantile Trust Co. purchased a new position in Agios Pharmaceuticals during the third quarter valued at $44,000. Wealthstreet Investment Advisors LLC lifted its holdings in Agios Pharmaceuticals by 10.9% during the third quarter. Wealthstreet Investment Advisors LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $1,037,000 after purchasing an additional 3,185 shares in the last quarter. California Public Employees Retirement System lifted its holdings in Agios Pharmaceuticals by 40.9% during the third quarter. California Public Employees Retirement System now owns 86,400 shares of the biopharmaceutical company’s stock valued at $2,799,000 after purchasing an additional 25,100 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Agios Pharmaceuticals by 430.6% during the third quarter. Steward Partners Investment Advisory LLC now owns 1,109 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 900 shares in the last quarter.

In other Agios Pharmaceuticals news, CEO Jacqualyn A. Fouse purchased 40,322 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were purchased at an average cost of $31.00 per share, with a total value of $1,249,982.00. Following the completion of the purchase, the chief executive officer now owns 41,722 shares in the company, valued at approximately $1,293,382. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David P. Schenkein purchased 8,064 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was acquired at an average cost of $31.00 per share, for a total transaction of $249,984.00. Following the completion of the purchase, the director now owns 97,567 shares of the company’s stock, valued at approximately $3,024,577. The disclosure for this purchase can be found here. Over the last three months, insiders bought 451,611 shares of company stock worth $13,999,941. Insiders own 3.16% of the company’s stock.

AGIO has been the topic of several recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Agios Pharmaceuticals in a report on Tuesday, November 26th. They set an “overweight” rating and a $64.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday. Guggenheim raised shares of Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Monday, September 23rd. Piper Jaffray Companies decreased their price objective on shares of Agios Pharmaceuticals from $80.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Finally, Citigroup decreased their price objective on shares of Agios Pharmaceuticals from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company. Agios Pharmaceuticals has an average rating of “Buy” and a consensus target price of $63.18.

NASDAQ:AGIO opened at $46.70 on Friday. The company’s 50-day moving average price is $36.76 and its 200-day moving average price is $40.61. The company has a current ratio of 5.30, a quick ratio of 5.24 and a debt-to-equity ratio of 0.24. The company has a market cap of $2.75 billion, a P/E ratio of -7.74 and a beta of 2.27. Agios Pharmaceuticals Inc has a twelve month low of $28.36 and a twelve month high of $68.94.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.85) by $0.04. The firm had revenue of $26.02 million for the quarter, compared to the consensus estimate of $33.13 million. Agios Pharmaceuticals had a negative net margin of 356.42% and a negative return on equity of 70.07%. The company’s revenue for the quarter was up 71.2% on a year-over-year basis. During the same period last year, the firm posted ($1.63) earnings per share. On average, analysts expect that Agios Pharmaceuticals Inc will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Read More: What does earnings per share mean?

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.